Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 351: What is the half-life of basiliximab?

A. 7 days (Correct Answer)
B. 7 hours
C. 15 days
D. 24 hours

Explanation: **Explanation:** **Basiliximab** is a chimeric monoclonal antibody that acts as an **IL-2 receptor antagonist**. It specifically binds to the **α-chain (CD25)** of the IL-2 receptor on activated T-lymphocytes, thereby preventing T-cell proliferation. It is primarily used for the induction of immunosuppression to prevent acute organ rejection in renal transplants. 1. **Why Option A is Correct:** The terminal elimination half-life of basiliximab is approximately **7 days** (ranging from 4 to 10 days). This prolonged half-life is characteristic of monoclonal antibodies (IgG1 isotype), which are protected from rapid degradation by the neonatal Fc receptor (FcRn). Clinically, a two-dose regimen (Day 0 and Day 4) provides adequate receptor saturation for approximately 30–45 days, covering the critical early post-transplant period. 2. **Why Other Options are Incorrect:** * **Option B (7 hours) & D (24 hours):** These are too short for monoclonal antibodies. Small molecule drugs or fragments (like Fab fragments) may have half-lives in this range, but intact chimeric antibodies circulate much longer. * **Option C (15 days):** While some monoclonal antibodies like Daclizumab (a humanized IL-2 antagonist) have a longer half-life of approximately 20 days, Basiliximab’s half-life is specifically shorter, centered around 7 days. **High-Yield NEET-PG Pearls:** * **Mechanism:** Competitive inhibition of IL-2 mediated activation of lymphocytes (CD25 blockade). * **Clinical Use:** Prophylaxis of **acute renal transplant rejection** (not for treating ongoing rejection). * **Adverse Effects:** Generally well-tolerated; unlike Muromonab-CD3, it does **not** cause cytokine release syndrome. * **Comparison:** **Daclizumab** (longer half-life, ~20 days) has been largely withdrawn from markets due to safety concerns, making Basiliximab the primary IL-2 antagonist in use.

Question 352: Which route of drug administration avoids first-pass hepatic metabolism and is used for drug preparations that slowly release drugs for periods as long as seven days?

A. Topical
B. Transdermal (Correct Answer)
C. Sublingual
D. Oral

Explanation: **Explanation** The correct answer is **Transdermal (Option B)**. **Why Transdermal is Correct:** The transdermal route involves the application of a drug to the skin (usually via a patch) for systemic absorption. It bypasses the gastrointestinal tract and the portal circulation, thereby **avoiding first-pass hepatic metabolism**. A key characteristic of transdermal delivery systems (TDS) is their ability to provide a **controlled, sustained release** of medication. This maintains steady-state plasma concentrations for extended periods, ranging from 24 hours to as long as **seven days** (e.g., Scopolamine or Clonidine patches). **Why Other Options are Incorrect:** * **Topical (A):** While applied to the skin, topical administration is intended for **local effect** (e.g., clotrimazole cream for fungal infections) rather than systemic absorption. * **Sublingual (C):** This route bypasses first-pass metabolism by absorbing drugs directly into the systemic circulation via the sublingual mucosa. However, it is used for **rapid onset** of action (e.g., Nitroglycerin for angina) and cannot provide sustained release for several days. * **Oral (D):** This is the most common route but is subject to significant **first-pass metabolism** in the liver and gut wall. It generally requires frequent dosing compared to long-acting patches. **NEET-PG High-Yield Pearls:** * **Drugs given via Transdermal Patch:** Nitroglycerin, Fentanyl (3 days), Nicotine, Hyoscine (3 days), Granisetron (7 days), and Hormonal contraceptives. * **Ideal Drug Properties for Transdermal Route:** Low molecular weight (<500 Da), high lipid solubility, and high potency (effective at low doses). * **Pro-tip:** The rate-controlling step in transdermal absorption is typically the **stratum corneum** of the epidermis.

Question 353: Disulfiram acts by competitive inhibition of which enzyme?

A. Alcohol dehydrogenase
B. Aldehyde dehydrogenase (Correct Answer)
C. Alcohol carboxylase
D. Aldehyde carboxylase

Explanation: **Explanation:** **1. Why Aldehyde Dehydrogenase is Correct:** The metabolism of ethanol follows a two-step oxidative pathway. First, ethanol is converted to **acetaldehyde** by alcohol dehydrogenase. Second, acetaldehyde is converted to **acetic acid** by the enzyme **Aldehyde Dehydrogenase (ALDH)**. Disulfiram acts by irreversibly inhibiting Aldehyde Dehydrogenase. This leads to a toxic accumulation of acetaldehyde in the blood if alcohol is consumed. High levels of acetaldehyde trigger the **Disulfiram-like reaction**, characterized by flushing, tachycardia, palpitations, nausea, and hypotension. This serves as a form of aversion therapy in chronic alcoholism. **2. Analysis of Incorrect Options:** * **Option A (Alcohol Dehydrogenase):** This enzyme is inhibited by **Fomepizole**, which is used in the treatment of methanol and ethylene glycol poisoning to prevent the formation of toxic metabolites (formaldehyde and glycolic acid). * **Options C & D (Alcohol/Aldehyde Carboxylase):** These are distractors. Carboxylase enzymes are involved in adding CO2 groups (often requiring Biotin) and do not play a role in the primary metabolic pathway of ethanol. **3. Clinical Pearls for NEET-PG:** * **Mechanism:** Disulfiram is an irreversible inhibitor (though the question uses the term "competitive," it is classically described as irreversible/non-competitive in advanced kinetics). * **Disulfiram-like reaction drugs:** Several other drugs can cause this reaction when taken with alcohol. High-yield examples include **Metronidazole** (most common), **Tinidazole**, **Cefotetan**, **Cefoperazone**, and **Chlorpropamide**. * **Acetaldehyde Syndrome:** The physiological distress caused by this reaction is the basis for its use in maintaining abstinence.

Question 354: A volunteer is to receive a new drug in a phase I clinical trial. The clearance and the volume of distribution of the drug in the volunteer are 1.386 L/hr and 80 L respectively. What would be the approximate half-life of the drug?

A. 83 hr
B. 77 hr
C. 40 hr (Correct Answer)
D. 0.02 hr

Explanation: The half-life ($t_{1/2}$) of a drug is the time required for its plasma concentration to decrease by 50%. It is a critical pharmacokinetic parameter used to determine dosing intervals and the time required to reach a steady state. **1. Why Option C is Correct:** The relationship between half-life ($t_{1/2}$), Volume of Distribution ($V_d$), and Clearance ($CL$) is defined by the following formula [2]: $t_{1/2} = \frac{0.693 \times V_d}{CL}$ Given values: * $V_d = 80 \text{ L}$ * $CL = 1.386 \text{ L/hr}$ Calculation: $t_{1/2} = \frac{0.693 \times 80}{1.386}$ $t_{1/2} = \frac{55.44}{1.386} = 40 \text{ hours}$ **2. Why Other Options are Incorrect:** * **Option A (83 hr) & B (77 hr):** These values result from calculation errors, such as incorrectly multiplying the variables or using an incorrect constant instead of 0.693. * **Option D (0.02 hr):** This value is obtained if the formula is inverted (Clearance divided by Volume of Distribution), which is mathematically incorrect for calculating half-life. **Clinical Pearls for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives** for a drug to reach a steady-state concentration ($C_{ss}$) during constant-rate infusion [3], [4]. * **Elimination:** Similarly, it takes about 4 to 5 half-lives for a drug to be effectively eliminated from the body after stopping the drug [3]. * **First-order Kinetics:** In first-order kinetics (most drugs), $t_{1/2}$ remains constant regardless of the dose [1]. In zero-order kinetics (e.g., high-dose Aspirin, Phenytoin, Ethanol), $t_{1/2}$ increases as the dose increases [1]. * **High-Yield Tip:** If you notice that $1.386$ is exactly $2 \times 0.693$, the calculation becomes much faster: $(0.693 \times 80) / (2 \times 0.693) = 80 / 2 = 40$.

Question 355: The redistribution phenomenon is observed in which of the following drugs?

A. Halothane
B. Ether
C. Thiopentone (Correct Answer)
D. All of the above

Explanation: **Explanation:** **1. Why Thiopentone is Correct:** Redistribution is the process where a drug moves from its primary site of action (highly perfused organs like the brain) to other tissues (muscle and fat) to achieve equilibrium. **Thiopentone**, a highly lipid-soluble ultra-short-acting barbiturate, exemplifies this. After IV bolus administration, it rapidly enters the brain, causing immediate anesthesia. However, its action terminates within minutes—not because of metabolism, but because the drug **redistributes** from the brain into the skeletal muscles and eventually adipose tissue, lowering the plasma concentration and allowing the patient to wake up. **2. Why Other Options are Incorrect:** * **Halothane and Ether (Options A & B):** These are volatile inhalational anesthetics. Their duration of action is primarily governed by their **solubility in blood** (blood-gas partition coefficient) and elimination via exhalation, rather than redistribution. While some redistribution occurs with all lipid-soluble drugs, it is not the clinically defining mechanism for the termination of action for these gases as it is for Thiopentone. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Context:** Redistribution is a major factor in the termination of action for **highly lipid-soluble** drugs given intravenously in a single bolus. * **Other Examples:** Apart from Thiopentone, **Propofol** and **Fentanyl** also exhibit significant redistribution. * **Cumulative Effect:** If Thiopentone is given as repeated doses or a continuous infusion, the storage sites (muscle/fat) become saturated. In this scenario, the duration of action depends on hepatic metabolism rather than redistribution, leading to prolonged recovery (the "hangover" effect). * **Key Concept:** Redistribution increases the **volume of distribution (Vd)** of a drug over time.

Question 356: A 75 kg person is administered a drug with a half-life of 3 hours. What is the approximate clearance of the drug?

A. 6770 mL/min
B. 1670 mL/min
C. 23 mL/min (Correct Answer)
D. 210 mL/min

Explanation: ⚠️ **Note:** This question cannot be solved using standard pharmacokinetic formulas without the volume of distribution (Vd). The answer relies on estimation principles rather than exact calculation. ***23 mL/min*** - This represents a **low to moderate clearance** value, typical for drugs that undergo hepatic metabolism with low-to-intermediate extraction ratios - For context: Normal **creatinine clearance** (marker of GFR) is approximately 90-120 mL/min in adults [1], so 23 mL/min represents roughly 20-25% of renal clearance capacity - This is a plausible value for drugs with **predominantly hepatic metabolism** with low hepatic extraction ratio - Using the relationship $Cl = \frac{0.693 \times Vd}{t_{1/2}}$, this would correspond to a Vd of approximately 6 liters (if t½ = 3 hours) [2] *210 mL/min* - This represents **moderate to high clearance**, suggesting efficient elimination - Comparable to **renal plasma flow** (approximately 600-700 mL/min × filtration fraction) - Would require a Vd of approximately 54 liters with the given half-life - Typical for drugs with good renal excretion or intermediate hepatic extraction *1670 mL/min* - This is extremely high clearance, approaching **total hepatic blood flow** (1500 mL/min) - Would require Vd of approximately 433 liters, which exceeds total body water (42L in a 70kg person) - Only seen with high extraction ratio drugs (>0.7) with extensive first-pass metabolism - Physiologically implausible for most drugs *6770 mL/min* - This clearance is **physiologically impossible** as it exceeds cardiac output (5-6 L/min = 5000-6000 mL/min) [3] - Clearance cannot exceed the blood flow to the eliminating organ [3] - Clearly a distracter option with no pharmacokinetic validity

Question 357: Which statement best describes the relationship between drug potency and efficacy in dose-response curves?

A. Drug C is as efficacious as drug D
B. Drug D is more potent than drug C
C. Drug B is the most efficacious (Correct Answer)
D. Drug C is the most potent

Explanation: ***Drug B is the most efficacious*** - **Efficacy** refers to the **maximum effect (Emax)** a drug can produce, represented by the plateau height of the dose-response curve on the y-axis - **Drug B's curve reaches the highest point**, indicating it produces the greatest maximal blocking effect (~100 units) - **This makes Drug B the most efficacious drug** among the three, as it can produce the largest therapeutic response regardless of how much drug is given - Efficacy order: Drug B > Drug C > Drug D *Drug C is the most potent* - **Potency** refers to the amount of drug needed to produce a given effect, measured by **EC50** (the concentration producing 50% of maximal effect) - **The lower the EC50, the more potent the drug** (curve shifted to the left) - **Drug B has the lowest EC50** (its curve is furthest to the left), making it the most potent drug, not Drug C - Drug C requires a higher concentration than Drug B to achieve 50% effect, so it is less potent - Potency order: Drug B > Drug C > Drug D *Drug C is as efficacious as drug D* - **Drug C has higher efficacy than Drug D** because its curve reaches a higher plateau on the y-axis - Drug C achieves a maximal blocking effect of approximately 100 units, while Drug D reaches only approximately 75 units - **Different efficacy values** mean they are not equally efficacious - A drug's efficacy is independent of the dose required and depends only on the maximum achievable effect *Drug D is more potent than drug C* - **Drug C is actually more potent than Drug D**, not the reverse - Drug C's dose-response curve is **shifted to the left** of Drug D's curve, indicating a lower EC50 - This means **Drug C requires a lower concentration** to achieve 50% of its maximal effect compared to Drug D - The leftward shift indicates greater potency for Drug C

Question 358: Loading dose of an oral drug depends on all of the following except?

A. Volume of distribution
B. Half-life (Correct Answer)
C. Plasma concentration
D. Bioavailability

Explanation: ***Correct Answer: Half-life*** - **Half-life** primarily determines the **maintenance dose** and **dosing interval**, not the loading dose - The **loading dose (LD)** is calculated to rapidly achieve the desired therapeutic **plasma concentration** using the formula: **LD = (Cp × Vd) / F** - Half-life determines how long it takes to reach steady state (4-5 half-lives) and how frequently maintenance doses should be given - The loading dose bypasses the waiting time by immediately achieving therapeutic levels *Incorrect: Volume of distribution* - **Vd** is a mandatory parameter in the calculation of the loading dose formula - It determines how widely the drug distributes in the body relative to the target plasma concentration - A higher **Vd** necessitates a higher loading dose to saturate tissue binding sites and achieve therapeutic plasma levels quickly *Incorrect: Plasma concentration* - The loading dose is specifically calculated to quickly achieve the desired therapeutic **steady-state plasma concentration (Cp)** - The target concentration (Cp) is central to the loading dose calculation and appears in the numerator of the formula - The goal of the loading dose is to bypass the time required to reach this concentration with maintenance doses alone *Incorrect: Bioavailability* - **Bioavailability (F)** represents the fraction of the administered drug that reaches systemic circulation - It is crucial for oral drugs where absorption may be incomplete due to first-pass metabolism or incomplete absorption - The loading dose formula includes **F** in the denominator (LD = (Cp × Vd) / F) to adjust for incomplete absorption

Question 359: Sodium thiopentone is regarded as an ultrashort-acting drug due to

A. Short elimination half-life
B. Metabolism
C. Excretion
D. Rapid redistribution (Correct Answer)

Explanation: ***Rapid redistribution*** - The ultrashort action of **thiopentone** is primarily due to its rapid **redistribution** from the central compartment (brain) to peripheral tissues (muscle and fat). - This rapid drop in plasma and brain concentration leads to swift termination of the drug's hypnotic effect. *Metabolism* - While thiopentone is metabolized primarily by the **liver**, its metabolic clearance is relatively slow, contributing to its long elimination half-life rather than its quick onset/offset. *Excretion* - Thiopentone is only minimally excreted unchanged by the **kidneys**; renal excretion is not the reason for the ultrashort duration of action. *Short elimination half-life* - Thiopentone actually has a **long elimination half-life** (around 10–12 hours) because of its high lipid solubility, long protein binding, and slow systemic metabolism. - The duration of action is governed by redistribution, not by the elimination half-life.

Question 360: A 25-year-old woman going on a luxury holiday cruise has motion sickness. She is prescribed this transdermal scopolamine delivery patch. All are true about its usage except:

A. Postauricular hairless skin has best delivery
B. Contact with the exposed adhesive layer should be avoided to prevent contamination of fingers with scopolamine
C. Slow absorption with lack of first pass metabolism
D. Remove patch immediately if there is pupil constriction and sialorrhea (Correct Answer)

Explanation: ***Remove patch immediately if there is pupil constriction and sialorrhea*** - Scopolamine is an **anticholinergic drug**; its side effects typically include **mydriasis (pupil dilation)** and **xerostomia (dry mouth)**, not constriction and increased salivation. - Therefore, pupil constriction and sialorrhea are **not expected adverse effects** of scopolamine and would not be a reason to immediately remove the patch based on its direct pharmacological action. *Postauricular hairless skin has best delivery* - The **postauricular area (behind the ear)** is a common and recommended site for scopolamine patch application due to its relatively thin, hairless skin and good blood supply, facilitating consistent drug absorption. - This location minimizes interference from hair and movement, which could dislodge the patch or affect absorption. *Contact with the exposed adhesive layer should be avoided to prevent contamination of fingers with scopolamine* - Directly touching the adhesive side of the patch can **transfer scopolamine** to the fingers, potentially leading to systemic absorption if the fingers are then brought to the eyes or mouth. - Accidental systemic absorption can cause side effects like **mydriasis** or **dry mouth** even if the patch is correctly applied elsewhere. *Slow absorption with lack of first-pass metabolism* - Transdermal patches deliver medication directly into the bloodstream, bypassing the **liver's first-pass metabolism**. - This results in a **slower, more sustained release** and a more consistent plasma concentration of the drug compared to oral administration.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free